Martinez-Marti, Alex
Felip, Enriqueta
Mancuso, Francesco Mattia
Caratú, Ginevra
Matito, Judit
Nuciforo, Paolo
Sansano, Irene
Diaz-Mejia, Nely
Cedrés, Susana
Callejo, Ana
Iranzo, Patricia
Pardo, Nuria
Miquel, Josep Maria
Navarro, Alejandro
Vivancos, Ana
Sansó, Miriam http://orcid.org/0000-0001-7155-4041
Article History
Received: 12 April 2021
Revised: 31 August 2021
Accepted: 17 September 2021
First Online: 1 October 2021
Ethics approval and consent to participate
: Approval to use these tumour specimens was obtained from the institutional review board and performed in accordance with the Declaration of Helsinki. All samples were obtained with the patients’ informed consent.
: No individually identifiable data are presented.
: AMM provided consultation, attended advisory boards and/or speaker’s bureau for the following organisations: BMS, Roche, MSD, Pfizer, Boehringer-Ingelheim, AstraZeneca. EF provided consultation, advisory role and/or speaker’s bureau: AbbVie, AstraZeneca, Blueprint medicines, Boehringer-Ingelheim, BMS, Celgene, Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, MSD, Novartis, Pfizer, Roche, Takeda, Touchtime. PN provided consultation, advisory role and/or speaker’s bureau: Bayer, MSD, Novartis, and Targos. IS provided consultation, attended advisory boards and/or speaker’s bureau for the following organisations: Roche, Abbvie, MSD, Pfizer, Takeda, BMS. SC provided consultation, attended advisory boards and/or speaker’s bureau for the following organisations: BMS, Roche, Pfizer, Boehringer-Ingelheim, MSD Oncology, Amphera. AC provided consultation, attended advisory boards and/or speaker’s bureau for the following organisations: BMS, Roche, Pfizer, Boehringer-Ingelheim, MSD Oncology, Kyowa Kirin, Celgene. PI provided consultation, attended advisory boards and/or speaker’s bureau for the following organisations: BMS, Roche, MSD, Boehringer-Ingelheim, MSD Oncology, Rovi, Kyowa Kirin, Grunenthal Pharma S.A. NP provided consultation, attended advisory boards and/or speaker’s bureau for the following organisations: BMS, Roche, Pfizer, Boehringer-Ingelheim. AN provided consultation attended advisory boards and/or speaker’s bureau for the following organisations: BMS, Roche, Pfizer, Boehringer-Ingelheim, Oryzon Genomics. AV has participated in advisory boards for BMS, Guardant Health and Bayer, and has provided consultation for Sysmex. The remaining authors declare no competing interests.